Treatment Strategies for Managing Hepatotoxicity and Brain Metastases in KRAS G12C-Mutated NSCLC : Episode 6

Hepatotoxicity with KRASG12C Inhibitors in NSCLC

December 21, 2023

Opinion

Video

Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.

EP: 1.Current Treatment Landscape for KRASG12C-Mutated NSCLC

EP: 2.Treatment Options for KRASG12C Mutated NSCLC

EP: 3.KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC

EP: 4.KRYSTAL-7: Efficacy and Safety of Adagrasib with Pembrolizumab in Patients With Advanced KRASG12C Mutated NSCLC

EP: 5.Long-Term Outcomes of Sotorasib Efficacy in Patients With KRASG12C Mutated NSCLC

Now Viewing

EP: 6.Hepatotoxicity with KRASG12C Inhibitors in NSCLC

EP: 7.Sotorasib Versus Docetaxel for Previously Treated Patients With KRASG12C Mutated NSCLC: Data From CodeBreaK 200

EP: 8.Managing CNS Metastases in KRASG12C Mutated NSCLC

EP: 9.Future Directions in KRASG12C Mutated NSCLC

EP: 10.Experts Examine the Need for Targeted Therapy Options for KRAS G12C–Mutated NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!